SUNNYVALE, Calif., April 15 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announced multiple presentations covering its Btk and HDAC programs at the American Association for Cancer Research (AACR) 2010 Annual Meeting being held April 17-21 in Washington, DC.
“We are continuing our research to expand the clinical indications for the drugs in our pipeline,” said Dr. Joseph J. Buggy, Vice President of Research. “For example, while the Btk inhibitor PCI-32765 continues to show promise in clinical trials in patients with B cell lymphomas and leukemias, we are now seeing preclinical evidence that the compound may also be efficacious in mast cell-driven cancers, which include certain pancreatic tumors and melanomas. In addition, our HDAC inhibitor PCI-24781 is now showing synergy with bortezomib in several indications. Based on this discovery, and our previous work, we are planning Phase I/II trials with PCI -24781 in combination with a number of other chemotherapeutics in collaboration with our ex-US global partner, Les Laboratories Servier.”
About Pharmacyclics
Pharmacyclics, Inc.
